Dihydrofolate reductase inhibitor
Since folate is needed by rapidly dividing cells to make thymine, this effect may be used to therapeutic advantage. For example, methotrexate is used as cancer chemotherapy because it can prevent neoplastic cells from dividing. Bacteria also need DHFR to grow and multiply and hence inhibitors selective for bacterial vs. host DHFR have found application as antibacterial agents.
Classes of small-molecules employed as inhibitors of dihydrofolate reductase include diaminoquinazoline and diaminopyrroloquinazoline, diaminopyrimidine, diaminopteridine and diaminotriazines. The examples provided below are specific molecules belonging to one of the above-mentioned classes.
A variety of drugs act as inhibitors of dihydrofolate reductase:
- the experimental antimalarial and anti-toxoplasmosis compound JPC-2056
- Oral piritrexim, a treatment for metastatic urothelial cancer.
- Huennekens FM (1994). "The methotrexate story: a paradigm for development of cancer chemotherapeutic agents". Advances in Enzyme Regulation. 34: 397–419. PMID 7942284. doi:10.1016/0065-2571(94)90025-6.
- McGuire JJ (2003). "Anticancer antifolates: current status and future directions". Current Pharmaceutical Design. 9 (31): 2593–613. PMID 14529544. doi:10.2174/1381612033453712.
- Hawser S, Lociuro S, Islam K (March 2006). "Dihydrofolate reductase inhibitors as antibacterial agents". Biochemical Pharmacology. 71 (7): 941–8. PMID 16359642. doi:10.1016/j.bcp.2005.10.052.
- Srinivasan B, Skolnick J (May 2015). "Insights into the slow-onset tight-binding inhibition of Escherichia coli dihydrofolate reductase: detailed mechanistic characterization of pyrrolo [3,2-f] quinazoline-1,3-diamine and its derivatives as novel tight-binding inhibitors". The FEBS Journal. 282 (10): 1922–38. PMC . PMID 25703118. doi:10.1111/febs.13244.
- Srinivasan B, Tonddast-Navaei S, Skolnick J (October 2015). "Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase". European Journal of Medicinal Chemistry. 103: 600–14. PMID 26414808. doi:10.1016/j.ejmech.2015.08.021.
- Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R (March 2008). "Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo". PLoS Neglected Tropical Diseases. 2 (3): e190. PMC . PMID 18320016. doi:10.1371/journal.pntd.0000190.
- de Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J (February 1993). "Oral piritrexim, an effective treatment for metastatic urothelial cancer". British Journal of Cancer. 67 (2): 388–90. PMC . PMID 8431372. doi:10.1038/bjc.1993.71.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|